Cummings uses Trump drug-price meeting to push Medicare negotiation plan

Elijah Cummings Jason Chaffetz
Along with Rep. Peter Welch, Rep. Elijah Cummings met with President Donald Trump on Wednesday to talk drug prices and present a plan for Medicare price negotiations.

After some political tussling last month, congressional pharma watchdog Rep. Elijah Cummings finally met with President Donald Trump to talk drug prices. Unfortunately for pharma, Cummings used the Wednesday meeting to push his plan for Medicare price negotiations.

Along with Rep. Peter Welch, Cummings met with Trump to present a plan that would allow Medicare to negotiate Part D drug prices by striking a “non-interference clause” from current laws, according to a statement from the House Committee on Oversight and Government Reform.

Among other points, the proposal calls for a formulary to “leverage the purchasing power of the government,” according to the statement, and sets up a “fallback process” in case prospective negotiations are fruitless.

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

And the congressmen seem to have the president on their side; Cummings told reporters after the meeting that Trump was "enthusiastic" and said he'd push for their proposal, according to the Washington Post. Trump told HHS Secretary Tom Price—who also attended the meeting—to "get this done," according to Cummings.

RELATED: Drug price moves in ACA repeal? Nope. But a Trump tweet says a 'new system' is coming

The Wednesday session is the latest development in a Trump-Cummings exchange on drug prices, which began when the president saw Cummings address the issue on TV. Trump called Cummings to suggest a meeting. Then, last month, during a lengthy press conference, Trump said Cummings had dodged a meeting with him for political reasons.

Cummings fired back. “I have no idea why President Trump would make up a story about me like he did today,” he said in a statement.

RELATED: Congressional pharma critic Cummings hits back after Trump's erratic presser

Nonetheless, the group got together on Wednesday and had a “productive" exchange, the congressman said.

The lawmakers’ negotiation push is the latest in a series of political proposals that have kept pharma on the defensive amid a growing swell of attention to U.S. drug prices. Just last week, Cummings joined a group of lawmakers who presented new legislation calling for importation from Canada; that group also seeks Trump’s support.

RELATED: Rolling out new importation bill, Sanders, Cummings urge Trump to step up on drug prices

After confusion on the Medicare negotiation issue last month, White House spokesperson Sean Spicer said the president is still “absolutely” in favor of the price-fighting measure.

The drug industry is not, and that's one reason the original Part D legislation did not allow Medicare to directly negotiate prices. Proposals to lift that restriction have cropped up in Congress repeatedly, but, partly because of pharma's powerful lobbying, those measures have never passed.

RELATED: Tough luck, pharma. Trump may cut taxes and regulations, but he still backs Medicare price negotiation

On multiple occasions, the president has pledged to bring down prices by growing competition in the industry. On Tuesday, following the unveiling of the Republican healthcare bill, Trump teased a “new system” to address pricing on Twitter, leaving industry-watchers curious for more details.

Suggested Articles

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.

Alexion and Amgen reached a deal to put off a biosimilar challenger to Alexion's blockbuster rare disease med Soliris until March 2025.